Kazia Therapeutics logo
Kazia Therapeutics
KZIA | NASDAQ
Chart Builder DCF Calculator
$5.60
-$1.02 (-15.41%)
At close: Nov 16, 2026, 4:00 PM ET
$5.60
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:46 PM ET

Kazia Therapeutics Company Profile

Company profile explained

Company Profile

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key Executives

Name Position
John Edwin Friend Chief Executive Officer
James E. Levine Chief Financial Officer
Elissa C. Hansen ACSA FCIS GAIC Company Secretary
Jeffrey Bonacorda Vice President of Finance & Controller
Sudha Rao Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 02, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 22, 2026 424B3 Filing
Sep 22, 2026 424B3 Filing
Sep 22, 2026 424B3 Filing
Sep 22, 2026 424B3 Filing
Sep 22, 2026 6-K Filing
Sep 18, 2026 424B3 Filing
Sep 18, 2026 424B3 Filing
Sep 18, 2026 424B3 Filing
Sep 18, 2026 424B3 Filing
View All SEC Filings ➞
Kazia Therapeutics
Kazia Therapeutics logo
Country Australia
IPO Date Jan 6, 1999
Industry Biotechnology
Sector Healthcare
Employees 6
CEO John Friend

Contact Details

Three International Towers Sydney, NSW 2000 Australia

Stock Details

Ticker Symbol KZIA
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001075880
CUSIP Number 48669G303
ISIN Number US48669G3039
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.